CN106728468A - Prevent and treat the pharmaceutical composition of synovitis - Google Patents

Prevent and treat the pharmaceutical composition of synovitis Download PDF

Info

Publication number
CN106728468A
CN106728468A CN201611132988.2A CN201611132988A CN106728468A CN 106728468 A CN106728468 A CN 106728468A CN 201611132988 A CN201611132988 A CN 201611132988A CN 106728468 A CN106728468 A CN 106728468A
Authority
CN
China
Prior art keywords
pharmaceutical composition
ethanol
weight
weight portion
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611132988.2A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611132988.2A priority Critical patent/CN106728468A/en
Publication of CN106728468A publication Critical patent/CN106728468A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical composition of synovitis and preparation method thereof is prevented and treated the invention discloses a kind of, pharmaceutical composition of the present invention is with convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb as bulk drug, proportioning is formed, routinely various formulations can be made by preparation process, prevent and treat synovitis evident in efficacy.

Description

Prevent and treat the pharmaceutical composition of synovitis
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for preventing and treating synovitis and its preparation side Method.
Background technology
Chronic knee synovitis is mainly developed by knee joint trauma or chronic strain, with gonalgia, is swollen It is swollen, activity it is unfavorable be characterized, treatment be easily caused synarthrophysis, moving obstacle, and then atrophy of quadriceps femoris, knee joint not in time Hypertrophy, forms " arthroncus of knee ", has a strong impact on the quality of life of patient.Its course of disease is long, easily repeatedly, using western medicine medicine time Long, adverse drug reaction is big, and the Patient drug's adverse reaction particularly with old kidney deficiency and liver is more obvious.Chronic knee is slided Film inflammation is the chronic aseptic inflammatory reaction of a kind of synovial membrane caused by wound or chronic strain, with synovial membrane hyperemia, oedema, thicken for Pathological characters.Pathological change is synovial membrane blood vessel dilatation, and diffusate largely increases, and blood plasma and cell exosmose, while synovial cell lives Jump, secretes a large amount of mucoitins and cellulose.If treatment can occur plump synovial membrane, fibrosis and synarthrophysis, serious shadow not in time Ring knee joint function.This disease category Chinese medical ' arthralgia syndrome ', " injury of tendon and muscle ", " traditional Chinese medical science injury of tendon and muscle seam " category, the cause of disease are to feel wind again after wound is strained Cold-dampness is evil and send out.Body is damaged in outer, then qi and blood is hindered in interior, and the long insufficiency of vital energy and blood of wound strain, wind-cold damp pathogen is taken advantage of a weak point, numbness resistance Channels and collaterals, retardance qi and blood, form weakened body resistance, the wet poly-, pathogenic characteristic of stasis blocking, not general rule bitterly, it is wet it is poly- then swell, the stasis of blood changes heat long, forms swollen The clinical symptoms of hot pain.《Prescriptions for Succouring the Sick numbness》Point out：" all because physically weak, space between skin and muscles is empty, and moisture of having a cold forms numbness ".If too late When the long Jinsuo roulade for the treatment of, dysarthrasis enlargement, ossifing to bend and stretch, and form " heumatism ", " stupid numbness ", " severe and migratory arthralgia ", serious shadow Ring minimal invasive treatment.
Convolvulate asiabell root：Block is dryly descended for Campanulaceae convolvulate asiabell root Codonopsis convolvulacea kurz Stem.Autumn takes stem tuber and cleans soil, dries.【Nature and flavor】It is sweet, slight bitter, puckery, it is micro- cool.【Function with cure mainly】Invigorating QI and blood, invigorating the spleen, Replenishing body fluid and clearing away heat pathogen.For catching a cold, cough, tonsillitis, pectoralgia, poor appetite is malnutritive.【Proterties】This product is in irregular ovum It is circular, circular, 2~3cm of major diameter, 13~28mm of minor axis.Surface taupe, canescence or filbert, have irregular mark of fibrous root. Crust is peeled off in the form of sheets, and crust shows off-white color, yellowish white or light isabelline after coming off, and shrinkage is uneven, there is vertical or horizontal ditch Line, there is slightly raised mark of fibrous root.Stem trace is arranged at top, there is fine and closely woven ring-type texture at nearly stem trace.Matter is more solid, after crushing, section Yellowish white or white powder, show slightly cutin shape.Gas is micro-, and taste is sweet, slight bitter.Record and issue Tibetan medicine standard in the Ministry of Public Health（First）, mark Quasi- numbering：WS3-BC-0051-95.
Three-jaw gold dragon：It is Vitaceae Parthenocissus plant parthenocissus himalayana Plancs Parthenocissus himalayana （Royle）Planch. the complete stool of ［ Ampelopsis himalayana Royle ］.Autumn, winter harvesting root and stem, cut after cleaning Piece or segment, dry.Summer, autumn picking leaves, dry.【Nature and flavor】It is pungent；Temperature.【Indication】Dispelling wind and eliminating dampness；Dissipate blood stasis and smoothing collaterals.Main wind Arthritis with fixed pain caused by dampness is bitterly；Traumatic injury；Fracture.【Former phytomorph】Parthenocissus himalayana Plancs fallen leaves woody climber.Multi-branched, branch is sturdy, drabon Color；Tendril is short and branch, and there is sucker on top.The leaflet alternate of palmate 3；Common petiole 5-12cm long, without hair or hairiness；Blade papery, Middle leaflet is avette or width drape over one's shoulders needle-like avette, 6-12cm long, 2-7cm wide, and tip is tapering or nearly shape of tail, and base portion wedge shape, side life is small Leaf is asymmetric, tiltedly avette, compared with the middle of leaflet it is smaller, edge have substantially and the sawtooth with tip, above without hair, below or along vein There is thin pubescence；Petiolule 5-6mm long.Flower both sexes, cyme be often born in brachyplast top or with leaf opposite；Bennet is compared with petiole It is short；Flower light green, 5 numbers 4 are counted sometimes；Calyx shallow disc shape, full edge；Petal Long Circle；Stamen and petal opposite；Floral disc is not obvious； Style short cylindrical shape, tip often expands discoid after petal comes off.Berry is spherical, ripe time-varying dark brown, has white powder, seed 1-2 .Record in dictionary of medicinal plant.
Small purpleflower stonecrop herb：It is complete for the small purpleflower stonecrop herb Petrocosmea minor Hemsl. of Gesneriaceae Petrocosmea plant Grass.The 7-9 months harvest, and clean, and dry.Seed is small, oval, smooth.【Nature and flavor】Taste micro-pungent；It is mild-natured.【Indication】Dissipate wind-heat; Invigorating the spleen disperse accumulations.Main cold, fever；Infantile malnutrition.【Former phytomorph】The small perennial small grass of purpleflower stonecrop herb acaulescence.Rhizome is short and thick, to Under close raw fibrous fibrous root.Phyllopodium gives birth to, 15-40 pieces;Leaf tool short handle or the stockless of inner face, outside leaf tool handle, up to 4cm, close quilt The pubescence of shape swallowtail;Blade ellipticity whip shape, oval or subcircular, 1-2.5cm long, 8-15mm wide, the micro- point of tip, base portion Wide wedge shape or wedge shape, ellipse, full edge or have unconspicuous wavy small knuckle-tooth, green above leaf, below light green, the close quilt in two sides The pubescence of development.Flower 1-5 bars, there is 1 (- 2) flower per inflorescence;Peduncle 3.5-7.5cm long, by development pubescence;Bract is narrow linear, 3mm is about, it is close by pubescence;Calyx 5 is split up to base portion, sliver wire lanceolar, and outside is by pubescence;Corolla purple, outside is by short soft Hair, corolla tube is short, 2.5-3.5cm long, is preced with the lip of mast two, upper lip ovate triangle, tip fine fisssure or nearly full edge, and lower lip 3 splits, sliver Near to wait big, tip is circular;Can educate stamen 2, filigree suede shape wide, close by brown undercoat, flower pesticide is about 5mm, staminodium 2;Ovary Close to lie prostrate pubescence by patch, style is about 7mm, and, by short volt hair, column cap is small, point-like for usual base portion.Capsule Long Circle, up to 10mm, By pubescence, room antiform is 2 valves.Seed is small, oval, smooth.The month at florescence 8-9, the fruiting period 10-11 months.Record in the big diction of Chinese medicine Allusion quotation.
Anisodine（Anisodine）：CAS 52646-92-1, molecular formula C17H21NO5, molecular weight 319.36.【Biology is living Property】Anticholinergic, antispastic, salivary secretion inhibitor, mydriasis.【Ingredient origin】Hide eggplant Anisodus tanguticus [Syn. Scopolia tangutica]。
Nerolidol（Nerolidol）：CAS 7212-44-4, molecular formula C15H26O, molecular weight 222.37.【Composition comes Source】Ginger Zingiber officinale.
2 bulk drug chemical constitutions：
Nerolidol（Nerolidol）Anisodine（Anisodine）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided it is a kind of effectively prevent and treat synovitis pharmaceutical composition and Its preparation method.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition for preventing and treating synovitis be：
Convolvulate asiabell root 5200-5300 weight portions three-jaw gold dragon 420-430 weight portion anisodine 230-260 weight portion nerolidols The small purpleflower stonecrop herb 700-900 weight portions of 50-60 weight portions.
The pharmaceutical composition for preventing and treating synovitis is preferably used in, is made up of the bulk drug of following weight portion：
The weight portion gravelstone of 245 weight portion nerolidol of the weight portion three-jaw of the convolvulate asiabell root 5250 imperial 425 weight portion anisodine of gold 55 The weight portion of butterfly 800.
A kind of pharmaceutical composition for preventing and treating synovitis, it is characterised in that pharmaceutical composition can be using the routine side of galenic pharmacy Method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating synovitis, it is characterised in that pharmaceutical composition is anti-with what chemical drugs or Chinese medicine were constituted Control synovitis medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating synovitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Convolvulate asiabell root 5200-5300 weight portions three-jaw gold dragon 420-430 weight portion anisodines The 230-260 weight portion small purpleflower stonecrop herb 700-900 weight portions of nerolidol 50-60 weight portions；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for preventing and treating synovitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The imperial weight portion of 425 weight portion anisodine 245 of the weight portion three-jaw of convolvulate asiabell root 5250 gold The small weight portion of purpleflower stonecrop herb 800 of the weight portion of nerolidol 55；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating synovitis, it is characterised in that pharmaceutical composition can use preparation Conventional method prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for preventing and treating synovitis, it is characterised in that pharmaceutical composition and chemical drugs or in Medicine composition prevents and treats synovitis medicine.
It is evident in efficacy that pharmaceutical composition prevents and treats synovitis.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of synovitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of synovitis be：Convolvulate asiabell root 5250g three-jaws gold dragon 425g The small purpleflower stonecrop herb 800g of anisodine 245g nerolidols 55g；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of synovitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of synovitis be：Convolvulate asiabell root 5200g three-jaws gold dragon 430g The small purpleflower stonecrop herb 700g of anisodine 230g nerolidols 60g；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of synovitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of synovitis be：Convolvulate asiabell root 5300g three-jaws gold dragon 420g The small purpleflower stonecrop herb 900g of anisodine 260g nerolidols 50g；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 188g of Example 1, adds starch 250g, mixes, and granulation is dried, plus microcrystalline cellulose 103g, stearic Sour magnesium 7g, mixes, and is pressed into 1100, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 368g of Example 2, adds starch 452g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 2200, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 430g water-baths and boil molten, add the pharmaceutical composition 24.4g of embodiment 3, fully Stir, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.5cm away from liquid level, and drop speed is optimum condition with every point 50 drop, and the cold of dripping pill surface is blotted with cotton Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：Prevent and treat the pharmaceutical composition of synovitis
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of synovitis be：
The three-jaw gold small weight portion of purpleflower stonecrop herb 860 of the imperial weight portion of 480 weight portion nerolidol 65.
Embodiment 8：Prevent and treat the pharmaceutical composition of synovitis
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of synovitis be：
The small weight portion of purpleflower stonecrop herb 950 of the weight portion of 240 weight portion nerolidol of anisodine 70.
Embodiment 9：Prevent and treat the pharmaceutical composition of synovitis
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of synovitis be：
The small weight portion of purpleflower stonecrop herb 750 of the weight portion of 270 weight portion nerolidol of anisodine 50.
Experimental example 1：Prevent and treat the experimental study of synovitis
1 data and method
1.1 physical data
This group 46, man 23, female 23；It is the oldest 60 years old, minimum 35 years old, average 51 years old；The course of disease is most long 1 month, most short by 5 My god, average 10 days.
1.2 diagnostic criteria
Foundation《Chinese medical disease Standardization of diagnosis and curative effect》In it is damp and hot accumulate resistance type gonarthromeningitis diagnostic criteria formulation.1. knee joint is red Swollen, pain；2. floating patella test is positive, and arthrocentesiS is light yellow transparent liquid；3. it is yellow with heating, urine.Red tongue with yellowish fur, arteries and veins Number.
1.3 include and exclusion standard
Meet above-mentioned diagnostic criteria, the age is between 35 years old~60 years old.Exclude knee tumor, tuberculosis, osteomyelitis and skin Allergy, can not be by scheme partner treatment person.
1.4 methods
1.4.1 group technology
Satisfactory 46 patients are divided into control group and treatment group, every group 23 by table of random number.Treatment group man 13, Female 10,35 years old~60 years old age, average 47.5 years old, the course of disease 5 to 30 days；Control group man 10, female 13,35 years old -60 age Year, average 52.5 years old, the course of disease 3 to 28 days；Two groups of Genders, age, course of disease aspects compare, and no significant difference has Comparativity.
1.4 treatment methods
Treatment group uses pharmaceutical composition（The pharmaceutical composition of embodiment 1）Stain of collapsing coordinates oral ibuprofen spansule (factory Family：Sino-America Tianjin Shike Pharmaceutical Co., Ltd., authentication code：Chinese medicines quasi-word H10900089), specification：0.39, once a grain, one Day 2 times (sooner or later respectively once).Pharmaceutical composition is ground into powdery, and pasty state is tuned into right amount with vinegar, is directly applied to affected part, thickness about 3mm, Overcoating preservative film, retention time 4 hours.Control group uses merely oral ibuprofen spansule (manufacturer：Sino-U.S.'s Tianjin history Gram pharmaceutical Co. Ltd, authentication code：Chinese medicines quasi-word H10900089), specification：0.39, once a grain, 2 times a day (sooner or later each one It is secondary).All patients are lain up during treating, and reduction is walked down.
2 efficacy determinations and result
2.1 efficacy evaluations
Reference《Chinese medical disease Standardization of diagnosis and curative effect》Formulate.Cure：The swelling of patient's gonalgia disappears, and joint motion is normal, Floating kneecap experiment is negative.Take a turn for the better：Knee joint swelling pain substantially mitigates, and joint motion improves.Do not heal：Knee joint swelling pain is without changing Kind, knee articulation is punctured and still extracts a large amount of hydrops out without improvement, knee joint.Statistical method is carried out using SPSSl4.0 statistical softwares Statistical analysis, enumeration data is used, inspection.
2.2 treatment results
Treatment group cures 15, takes a turn for the better 6, not more 2, and total effective rate is up to 91.30%；Control group cures 8, takes a turn for the better 5, not More 10, total effective rate is up to 56.52%.Two groups of comparitive studies, the statistically significant (P of difference<0.05), show that treatment group is better than Control group.

Claims (8)

1. a kind of pharmaceutical composition for preventing and treating synovitis, it is characterised in that be made the composition and weight of the bulk drug of the pharmaceutical composition Measuring part is：
Convolvulate asiabell root 5200-5300 weight portions three-jaw gold dragon 420-430 weight portion anisodine 230-260 weight portion nerolidols The small purpleflower stonecrop herb 700-900 weight portions of 50-60 weight portions.
2. a kind of pharmaceutical composition for preventing and treating synovitis according to claim 1, it is characterised in that be made the pharmaceutical composition Bulk drug composition and weight portion be：
The weight portion gravelstone of 245 weight portion nerolidol of the weight portion three-jaw of the convolvulate asiabell root 5250 imperial 425 weight portion anisodine of gold 55 The weight portion of butterfly 800.
3. a kind of pharmaceutical composition for preventing and treating synovitis according to claim 1, it is characterised in that pharmaceutical composition can be adopted Piece agent or capsule or dripping pill are prepared with the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for preventing and treating synovitis according to claim 1, it is characterised in that pharmaceutical composition and chemistry What medicine or Chinese medicine were constituted prevents and treats synovitis medicine.
5. a kind of preparation method of the pharmaceutical composition for preventing and treating synovitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Convolvulate asiabell root 5200-5300 weight portions three-jaw gold dragon 420-430 weight portion anisodines The 230-260 weight portion small purpleflower stonecrop herb 700-900 weight portions of nerolidol 50-60 weight portions；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for preventing and treating synovitis according to claim 5, it is characterised in that by as follows It is prepared by step：
The composition and weight portion of bulk drug be：The imperial weight portion of 425 weight portion anisodine 245 of the weight portion three-jaw of convolvulate asiabell root 5250 gold The small weight portion of purpleflower stonecrop herb 800 of the weight portion of nerolidol 55；
Preparation method：
（1）Convolvulate asiabell root, three-jaw gold dragon, anisodine, nerolidol, small purpleflower stonecrop herb are taken by bulk drug proportioning, is mixed, use weight percent Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 37%, and extraction time is 9 times, and each extraction time is 45 hours, molten every time Agent consumption is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close Degree 1.17, filtration, liquid is first washed with water by LKS02 large pore resin absorption columns, then with the second of weight percent concentration 16.5% Alcoholic solution elutes LKS02 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 16.5%, reclaims ethanol, concentration Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 32 times is carried every time The time is taken for 0.1 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP825 large pore resin absorption columns, then with again Amount percent concentration 73% ethanol solution wash-out SP825 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 73% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for preventing and treating synovitis according to claim 5, it is characterised in that medicine group Compound can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. a kind of preparation method of the pharmaceutical composition for preventing and treating synovitis according to claim 5, it is characterised in that medicine group Compound prevents and treats synovitis medicine with chemical drugs or Chinese medicine composition.
CN201611132988.2A 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of synovitis Withdrawn CN106728468A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611132988.2A CN106728468A (en) 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of synovitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611132988.2A CN106728468A (en) 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of synovitis

Publications (1)

Publication Number Publication Date
CN106728468A true CN106728468A (en) 2017-05-31

Family

ID=58875848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611132988.2A Withdrawn CN106728468A (en) 2016-12-10 2016-12-10 Prevent and treat the pharmaceutical composition of synovitis

Country Status (1)

Country Link
CN (1) CN106728468A (en)

Similar Documents

Publication Publication Date Title
CN100542585C (en) A kind of externally-applied medicinal composition with analgesia and antiinflammatory action
KR101348102B1 (en) A composition comprising extracts of herbal mixture for treating or preventing interstitial cystitis
CN105031408B (en) A kind of composition improving gout
CN106728468A (en) Prevent and treat the pharmaceutical composition of synovitis
CN102727804B (en) Traditional Chinese medicine composition for treating abscess and boil and preparation method thereof
CN104721248B (en) Composition with antidepressant effect and application thereof
CN106727752A (en) Treat pharmaceutical composition of synovitis and preparation method thereof
CN104306585B (en) One kind is used to treat prostatitic Chinese medicine composition and preparation method and application
CN116115687B (en) Traditional Chinese medicine composition for gout and preparation method and application thereof
CN102370937B (en) Traditional Chinese drug composition for treating breast benign hyperplasia diseases, and preparation method thereof
CN106727789A (en) The treatment cold arthritic pharmaceutical composition of rheumatism
CN106692503A (en) Pharmaceutical composition for prevention and treatment of tuberculosis and preparing method thereof
TWI535447B (en) Herbal extract for inhibiting growth of tumor
CN106470694A (en) For improving the Orally administered composition of the General Symptomies including cold sensitivity
CN117695362A (en) Pharmaceutical composition for treating chronic glomerulonephritis and preparation method and application thereof
CN106728470A (en) Pharmaceutical composition of anti-rheumatism treating and preparation method thereof
CN106727875A (en) Treat pharmaceutical composition of rheumatism and preparation method thereof
CN102670986B (en) Use of Chinese medicinal compound with tongue squamous cell carcinoma resisting effect in preparing the medicine for tongue squamous cell carcinoma
CN104042924A (en) Chinese herba preparation capable of treating qi and blood deficiency osteoarthritis and preparation method thereof
CN107854626A (en) A kind of medicinal liquor of relaxing tendons and activating collaterals and preparation method thereof
CN106728431A (en) A kind of pharmaceutical composition for treating gonarthromeningitis
CN113713019A (en) Traditional Chinese medicine composition and application thereof in preparing medicine for treating thalassemia
CN106581134A (en) Pharmaceutical composition for preventing and treating synovitis
CN106729032A (en) Pharmaceutical composition for treating cold in children
CN105641217A (en) Pharmaceutical composition for treating prostatic hyperplasia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531

WW01 Invention patent application withdrawn after publication